Iradimed Corp Stock Receives Strong Buy Ratings from Analysts

robot
Abstract generation in progress

Iradimed Corp (NASDAQ: IRMD) has received “Buy” ratings from all three analysts covering the stock, with a median one-year target price suggesting a nearly 34% upside. This positive outlook is driven by the company’s unique position as the sole provider of non-magnetic MRI-compatible IV infusion pumps and patient monitoring systems, along with its product growth and potential for international expansion. Freedom Broker initiated coverage with a Buy rating and a $116 price target, highlighting Iradimed’s profitability and specialized product portfolio.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin